A combined in vitro and in vivo approach to evaluate wound healing management with a new healing dermocosmetic product

Aim

Applying a moisturizer is commonly practiced to support wound healing and reduce discomfort sensations, but few robust studies investigate the management of a moisturizer in wound healing. The study’s aim was to objectivate pro-wound healing effect of a dermocosmetic product, using a combined approach from in vitro to in vivo models versus control.

Method

The repair active ingredients were evaluated by using a 3D human bilayered skin equivalent wound healing model. Then a randomized double-blind study evaluated the skin regeneration after standardized skin abrasion in 24 subjects. The product was applied in a way once daily covered with a sterile dressing from day 1 (D1) to D7, then twice daily in open until D15. TEWL, images, clinical and functional signs were assessed at each visit vs untreated condition.

Results/Discussion

In the in vitro model, the ingredients improved wound closure (D7 91% vs 48% for untreated), epidermal regeneration (Ki67, loricrine, CD44) and dermal-epidermal junction structuration (collagen VII and XVII), and enhanced dermal repair (collagen III). . In vivo, lower TEWL values were obtained with the product at all time points, and significant between D5 and D4 (-13% vs -2% for untreated). Abrased areas were visually improved vs untreated area associated with significant less erythema (-21%) at D8 and an improved subjective global score (-55% discomfort) at D5, including burning (-64%), tingling sensations (-72%) and itching, with no adverse events.

Conclusion

This new healing dermocosmetic product contributes to a better skin repair and demonstrates significant beneficial activities on natural healing process.